title: Role of human herpesvirus 8 interleukin-6-activated gp130 signal transducer in primary effusion lymphoma cell growth and viability.
abstract: Human herpesvirus 8 (HHV-8) infection is associated with Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman's disease. HHV-8-encoded viral interleukin-6 (vIL-6) is believed to contribute to pathogenesis via proproliferative, antiapoptotic, and proangiogenic activities. In PEL cells, vIL-6 is produced in functional amounts during viral latency and promotes the growth of these cells, mediating its activity from the endoplasmic reticulum (ER), where it is predominantly localized. This vIL-6 activity is dependent, in part, on its interaction with a splice variant of vitamin K epoxide reductase complex subunit 1 (VKORC1), termed VKORC1 variant 2 (VKORC1v2). Here we report that the IL-6 signal transducer, gp130, which can support vIL-6 signaling from the ER, is also required for optimal PEL cell growth and viability. Levels of activated extracellular regulated kinases (ERKs) 1 and 2 and signal transducer and activator of transcription 1 (STAT1) and STAT3, phosphorylated following gp130 stimulation, were reduced in gp130-depleted BCBL-1 and BC-1 cells. Diminished STAT activation was also detected in JSC-1 and BC-3 cells. Effects of gp130 depletion on growth could be mimicked by short hairpin RNA targeting of ERKs 1 and 2 or by depletion of STAT3. Finally, inhibition of vIL-6-gp130 association specifically within the ER compartment suppressed cell proliferation and viability, mirroring the effects of gp130 depletion. Combined, these data demonstrate that gp130, in addition to VKORC1v2, is essential for normal PEL cell growth and survival and that ER-localized vIL-6-gp130 interactions are critical for these activities. Targeting of intracellular vIL-6-gp130 interactions could potentially provide a means of PEL therapy.
authors.affiliation: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
authors.forename: Emily
authors.initials: E
authors.lastname: Cousins
authors.forename: John
authors.initials: J
authors.lastname: Nicholas
mesh_terms: D000818:Animals; D017209:Apoptosis; D002453:Cell Cycle; D049109:Cell Proliferation; D050822:Cytokine Receptor gp130 / Q000378:metabolism*; D004721:Endoplasmic Reticulum / Q000378:metabolism; D019288:Herpesvirus 8, Human / Q000235:genetics*; D006801:Humans; D015151:Immunoblotting; D047468:Immunoprecipitation; D015850:Interleukin-6 / Q000378:metabolism*; D054685:Lymphoma, Primary Effusion / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D010766:Phosphorylation; D019947:Receptors, Interleukin-6 / Q000378:metabolism; D050796:STAT3 Transcription Factor / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D050796:STAT3 Transcription Factor; D050822:Cytokine Receptor gp130
references.citation: J Mol Biol. 2004 Jan 9;335(2):641-54
references.pmid: 14672670
references.citation: Blood. 2004 Dec 1;104(12):3712-21
references.pmid: 15297310
references.citation: J Gen Virol. 2006 May;87(Pt 5):1139-1144
references.pmid: 16603514
references.citation: Oncogene. 2000 May 15;19(21):2548-56
references.pmid: 10851053
references.citation: Curr Opin Oncol. 2012 Sep;24(5):495-505
references.pmid: 22729151
references.citation: J Virol. 2010 Jun;84(11):5565-73
references.pmid: 20219929
references.citation: J Virol. 2012 Feb;86(3):1577-88
references.pmid: 22130532
references.citation: Adv Cancer Res. 2001;81:161-200
references.pmid: 11430595
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4422-32
references.pmid: 19667270
references.citation: Stem Cells. 2007 Mar;25(3):779-89
references.pmid: 17158240
references.citation: J Virol. 2009 May;83(10):5117-26
references.pmid: 19264784
references.citation: Blood. 1999 Oct 15;94(8):2871-9
references.pmid: 10515891
references.citation: Front Biosci. 2007 Jan 01;12:265-81
references.pmid: 17127298
references.citation: J Virol. 2007 Mar;81(5):2449-58
references.pmid: 17151100
references.citation: J Pathol. 2006 Jan;208(2):187-98
references.pmid: 16362980
references.citation: J Virol. 2006 Sep;80(17):8510-20
references.pmid: 16912301
references.citation: J Virol. 2006 Jun;80(11):5371-82
references.pmid: 16699017
references.citation: J Biol Chem. 1997 Aug 1;272(31):19625-31
references.pmid: 9235971
references.citation: Oncogene. 2000 May 15;19(21):2474-88
references.pmid: 10851046
references.citation: J Interferon Cytokine Res. 2011 Nov;31(11):791-801
references.pmid: 21767154
references.citation: J Virol. 2008 Sep;82(17):8771-9
references.pmid: 18579585
references.citation: Acta Biochim Biophys Sin (Shanghai). 2008 Jun;40(6):519-25
references.pmid: 18535750
references.citation: J Biol Chem. 2006 May 19;281(20):14111-8
references.pmid: 16571725
references.citation: J Virol. 2006 Nov;80(21):10874-8
references.pmid: 16956953
references.citation: Virology. 2010 Jul 20;403(1):92-102
references.pmid: 20451233
references.citation: Blood. 2003 Feb 15;101(4):1535-42
references.pmid: 12393476
references.citation: J Virol. 1999 Oct;73(10):8268-78
references.pmid: 10482577
references.citation: Eur J Cancer. 2005 Nov;41(16):2502-12
references.pmid: 16199153
references.citation: Virology. 2008 Feb 5;371(1):139-54
references.pmid: 17964626
references.citation: Biochem J. 1998 Sep 1;334 ( Pt 2):297-314
references.pmid: 9716487
references.citation: Methods Mol Med. 2003;76:367-82
references.pmid: 12526175
references.citation: Nat Med. 1997 Mar;3(3):287-92
references.pmid: 9055855
references.citation: J Virol. 2005 Aug;79(16):10308-29
references.pmid: 16051824
references.citation: J Gen Virol. 2006 Apr;87(Pt 4):795-802
references.pmid: 16528027
references.citation: Blood. 2005 Aug 15;106(4):1382-91
references.pmid: 15890690
references.citation: J Virol. 2006 Oct;80(19):9811-21
references.pmid: 16973585
references.citation: J Virol. 2009 Jan;83(2):722-33
references.pmid: 18987143
references.citation: Antioxid Redox Signal. 2006 Mar-Apr;8(3-4):347-53
references.pmid: 16677080
references.citation: J Biol Chem. 2004 Dec 10;279(50):51793-803
references.pmid: 15258150
references.citation: Oncogene. 2005 Oct 27;24(47):7022-30
references.pmid: 16044161
references.citation: Nat Clin Pract Oncol. 2005 Jun;2(6):315-24
references.pmid: 16264989